As studies grow in size and complexity, sample preparation has become one of the key bottlenecks – impacting reproducibility, throughput, and scalability. To better understand how teams are navigating this, we asked the proteomics community across academia, pharma, clinical labs, and technology providers.
Bispebjerg Hospital has established a high-throughput LCMS platform and implemented a protein-based liver disease risk profile that can be ordered directly through an electronic healthcare system.
A new study in Nature Communications explores how LC-MS-based proteomics, combined with machine learning, could revolutionize diagnostics for neurological infections like Lyme neuroborreliosis.
Proteins are the most dynamic molecules in the body, directly influencing cellular health and function. They are also the primary targets for most therapeutic treatments. Through proteomics, we can gain valuable insights into drug efficacy and safety by monitoring proteins in real-time. Significant progress has been made in this field over the past few decades, with recent technological advancements – particularly in the last five years – dramatically increasing both the speed and robustness of proteomics.
Proteomics has revolutionized the field of biomarker discovery, offering unprecedented insights into cellular processes and disease mechanisms. However, as mass spectrometry (MS) technology advances, the bottleneck has shifted to the pre-analytical sample preparation phase. Evosep’s innovative solution addresses this challenge head-on with a fully automated, scalable workflow leveraging the Evotip platform.
